Ra Pharmctl Inc (RARX) Rating Reiterated by Jefferies Group LLC

Jefferies Group LLC reissued their buy rating on shares of Ra Pharmctl Inc (NASDAQ:RARX) in a research note released on Friday, July 14th. Jefferies Group LLC currently has a $25.00 price target on the stock.

Other research analysts have also issued reports about the company. Zacks Investment Research lowered Ra Pharmctl from a buy rating to a hold rating in a report on Thursday, May 25th. Credit Suisse Group reiterated an outperform rating and set a $19.00 price target on shares of Ra Pharmctl in a report on Tuesday, April 18th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Ra Pharmctl presently has a consensus rating of Buy and an average price target of $27.00.

Shares of Ra Pharmctl (RARX) traded up 4.69% during trading on Friday, reaching $15.39. 134,822 shares of the company’s stock were exchanged. The stock’s market capitalization is $347.31 million. The stock has a 50 day moving average price of $18.67 and a 200-day moving average price of $20.43. Ra Pharmctl has a 52 week low of $12.05 and a 52 week high of $27.84.

Ra Pharmctl (NASDAQ:RARX) last issued its quarterly earnings results on Thursday, May 11th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.08. Analysts predict that Ra Pharmctl will post ($2.12) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “[[title]]” was originally reported by [[site]] and is the sole property of of [[site]]. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at [[permalink]].

In other Ra Pharmctl news, major shareholder Bioventures Ltd Novartis sold 9,019 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $25.50, for a total value of $229,984.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 208,880 shares of company stock worth $4,946,431 over the last quarter. Company insiders own 14.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in shares of Ra Pharmctl by 3.6% in the first quarter. Wellington Management Group LLP now owns 1,631,429 shares of the company’s stock valued at $34,733,000 after buying an additional 56,450 shares during the last quarter. VHCP Management II LLC boosted its stake in shares of Ra Pharmctl by 33.6% in the first quarter. VHCP Management II LLC now owns 725,029 shares of the company’s stock valued at $15,436,000 after buying an additional 182,529 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Ra Pharmctl during the fourth quarter valued at approximately $5,560,000. Emory University acquired a new stake in shares of Ra Pharmctl during the first quarter valued at approximately $2,206,000. Finally, Geode Capital Management LLC boosted its stake in shares of Ra Pharmctl by 8.5% in the first quarter. Geode Capital Management LLC now owns 70,863 shares of the company’s stock valued at $1,508,000 after buying an additional 5,522 shares during the last quarter. Institutional investors own 61.81% of the company’s stock.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.